Page 76 — how dendritic cells capture, process, and display antigen as an MHC-peptide complex to prime antigen-specific naive T-cells in the lymph node
Immature dendritic cells (DCs) sit at the front line of the immune system, extending dendrites through peripheral tissues to sample their surroundings. Using phagocytosis, macropinocytosis, and receptor-mediated endocytosis, they internalize whole pathogens, cellular debris, and free-floating proteins. Once inside, these proteins are unfolded and cleaved by proteases in the endosomal/lysosomal pathway (for extracellular material bound for MHC class II) or by the proteasome in the cytosol (for intracellular/viral proteins bound for MHC class I), yielding short peptide fragments 8–25 amino acids long — the raw material for antigen presentation.
T-cell receptors cannot recognize whole, folded proteins the way antibodies can. They are built to read short linear peptides cradled in the groove of an MHC molecule. Breaking a pathogen or tumor protein down into fragments is therefore not incidental cleanup — it is the essential translation step that converts a biological threat into a molecular signal the adaptive immune system can interrogate.
Dendritic cells are uniquely good at this job compared to other antigen-presenting cells: they combine high rates of antigen uptake in their immature state with the machinery to route fragments efficiently toward both MHC class I and class II pathways, a property called cross-presentation that lets them prime both cytotoxic and helper T-cells against the same captured antigen.
Immature dendritic cells are optimized for capture, not activation — they have not yet turned on the costimulatory molecules required later in the pathway. This staged behavior helps prevent premature or inappropriate T-cell activation.
Once antigen has been chopped into peptide fragments, those fragments must be physically loaded into the peptide-binding groove of an MHC molecule before they can be displayed. This loading happens within specialized intracellular compartments — the endoplasmic reticulum for MHC class I, and the MIIC (MHC class II compartment) for MHC class II — where chaperone proteins hold the MHC molecule open until a peptide of appropriate length and anchor-residue chemistry locks into place, forming a stable MHC-peptide complex.
Not every peptide fragment gets loaded — MHC molecules are picky. Each MHC allele has a characteristic binding groove with pockets that favor peptides bearing specific "anchor residues" at defined positions. Only fragments with compatible anchor chemistry bind stably enough to survive the trip to the cell surface; poorly-fitting peptides are edited out by chaperones such as tapasin (class I) or HLA-DM (class II), which act as peptide quality-control checkpoints.
This editing step matters enormously for what happens downstream: only a stable, well-loaded MHC-peptide complex will persist on the dendritic cell surface long enough, and in high enough copy number, to be found and recognized by a rare antigen-specific naive T-cell during migration and lymph node scanning.
The peptide-loading step is a molecular filter: it converts a large, messy pool of protein fragments into a curated set of MHC-peptide complexes stable enough to serve as a reliable antigen fingerprint on the cell surface.
Antigen capture and MHC loading trigger dendritic cell maturation: the cell downregulates further antigen uptake, upregulates the chemokine receptor CCR7, and begins to migrate. Guided by CCR7 ligands (CCL19/CCL21) expressed along lymphatic vessels and within lymph node stroma, the maturing dendritic cell travels from peripheral tissue into the afferent lymphatics and arrives at the T-cell zone of a draining lymph node — the one anatomical location where it can efficiently meet the enormous, diverse repertoire of naive T-cells.
A single naive T-cell clone specific for any given antigen is exceedingly rare — often less than one in a million circulating T-cells. Finding that rare match by chance in open tissue would be statistically hopeless. Lymph nodes solve this search problem by concentrating naive T-cells into a dense, continuously recirculating population within a compact anatomical space, and by giving migrating dendritic cells a direct, chemokine-guided route to reach exactly that space.
Once inside the T-cell zone, the dendritic cell forms an extended dendritic network that dramatically increases the surface area available for scanning, letting many naive T-cells sequentially probe its presented MHC-peptide complexes within a short window of time.
Migration is not passive drift — it is an actively guided relocation that solves the needle-in-a-haystack problem of finding a rare antigen-specific T-cell among the huge naive repertoire.
Within the lymph node, naive T-cells continuously extend and retract membrane contacts as they probe dendritic cell surfaces, sampling many different MHC-peptide complexes per minute. Each T-cell carries a single TCR specificity, shaped by random V(D)J recombination during thymic development. When a T-cell whose TCR happens to fit the shape and chemistry of a particular MHC-peptide complex makes contact, the interaction persists — TCR and coreceptor (CD4 or CD8) cluster at the contact zone, forming the beginning of an immunological synapse. This is Signal 1: antigen-specific recognition.
TCR engagement of a matching MHC-peptide complex is the defining, antigen-specific event of T-cell priming — without it, there is no basis for the immune system to know which threat to respond to. But recognition by itself only delivers a partial signal into the T-cell. Sustained TCR engagement in the absence of additional cues triggers intracellular signaling that is deliberately incomplete, priming the cell for a second checkpoint rather than immediately driving full activation.
This built-in pause is a safety feature: it prevents a T-cell from launching a full effector response purely because it physically bumped into a matching peptide, decoupling molecular recognition from a decision that has significant physiological consequences.
Signal 1 (TCR-MHC-peptide engagement) establishes specificity — which threat — but the cell withholds full commitment until a second, independent signal confirms that the threat is genuine.
Complete activation of a naive T-cell requires two independent signals delivered together. Signal 1 comes from TCR engagement of the MHC-peptide complex. Signal 2 — costimulation — comes from surface molecules such as CD80/CD86 on the dendritic cell binding CD28 on the T-cell, and is only strongly upregulated on dendritic cells that have themselves received maturation signals from genuine danger cues (pathogen molecules, tissue damage, inflammatory cytokines). Only when both signals arrive together does the T-cell fully activate, proliferate, and differentiate into an effector cell.
The requirement for two independent, physically co-localized signals is one of the central safety mechanisms of adaptive immunity. A dendritic cell that has captured antigen without receiving genuine danger cues stays immature and expresses little costimulatory molecule — so even if a T-cell recognizes a presented complex on such a cell, it receives Signal 1 without Signal 2. The result is anergy: the T-cell becomes functionally unresponsive rather than activated, a built-in tolerance mechanism that helps prevent autoimmune responses against self-peptides that are routinely displayed at low levels.
Only when a dendritic cell has matured in the context of real infection or tissue damage — and therefore upregulated CD80/CD86 — does costimulation accompany antigen presentation. The coincidence of both signals is what the immune system treats as reliable evidence of genuine threat, licensing the T-cell to proliferate clonally and differentiate into effector cells that can leave the lymph node and act.
Two-signal activation (TCR-MHC-peptide specificity + costimulation) ensures that full immune activation only occurs when antigen recognition coincides with independent confirmation of danger — a molecular checks-and-balances system against autoimmunity.